Hospital
Brandywine Hospital, LLC
Brandywine Hospital, LLC was paid $2.97M by Medicaid between Aug 2019 and Jan 2022, across 109 billing codes. Its largest line is 99284, emergency room visit (serious) — 34% of everything it billed.
33Billing provider infoBRANDYWINE HOSPITAL, LLC
COATESVILLE, PA 19320
COATESVILLE, PA 19320
33aNPI1194249961assigned 08/02/2017
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.97M
24GClaims41,230
24DCodes billed109
24AFirst – last monthAug 2019 – Jan 2022
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#76 of 154
Median peer was paid$2.82M
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CONNER, GARY controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 467 | $6K | |
| 2020 | 10,635 | $660K | |
| 2021 | 29,779 | $2.22M | |
| 2022 | 349 | $85K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 34% | 5,116 | 4,674 | $1.02M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 3,013 | 2,863 | $629K |
| G0378 | Hospital observation service, per hour | 9.9% | 309 | 280 | $293K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 9.6% | 1,920 | 522 | $285K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.0% | 668 | 618 | $120K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.0% | 410 | 401 | $89K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.4% | 112 | 109 | $71K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 151 | 144 | $45K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 918 | 863 | $38K |
| 80053 | Comprehensive metabolic panel | 1.0% | 2,473 | 2,163 | $30K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 129 | 125 | $25K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 317 | 306 | $21K |
97 more codes
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 870 | $18K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 319 | $17K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 49 | $16K |
| 97161 | <1% | 156 | $15K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 687 | $15K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 476 | $13K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,365 | $13K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 104 | $12K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 355 | $11K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 46 | $10K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 55 | $10K |
| 87631 | <1% | 116 | $9K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 13 | $9K |
| 76830 | Ultrasound, transvaginal | <1% | 45 | $9K |
| 73630 | <1% | 86 | $8K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 3,028 | $8K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 777 | $8K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 129 | $8K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 257 | $7K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 870 | $7K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 12 | $6K |
| 71045 | Radiologic examination, chest; single view | <1% | 559 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 590 | $5K |
| 94060 | <1% | 13 | $3K | |
| 73610 | <1% | 45 | $3K | |
| 76642 | <1% | 14 | $3K | |
| 0001A | <1% | 90 | $3K | |
| 0002A | <1% | 83 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 706 | $2K |
| 84484 | <1% | 922 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 19 | $2K |
| 94729 | <1% | 13 | $2K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 113 | $2K |
| 93922 | <1% | 13 | $2K | |
| 85610 | <1% | 524 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 56 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 277 | $2K |
| 85027 | <1% | 95 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 425 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,516 | $2K |
| 94726 | <1% | 13 | $1K | |
| 73030 | <1% | 26 | $1K | |
| 85730 | <1% | 281 | $1K | |
| 73130 | <1% | 16 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 428 | $1K |
| 83880 | <1% | 199 | $1K | |
| 83690 | <1% | 694 | $929.72 | |
| 93971 | <1% | 12 | $896.82 | |
| 72100 | <1% | 14 | $856.67 | |
| 82550 | <1% | 459 | $753.91 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 33 | $748.70 |
| 84703 | <1% | 83 | $745.29 | |
| 82248 | <1% | 329 | $599.74 | |
| 81025 | <1% | 649 | $588.85 | |
| 73110 | <1% | 12 | $567.87 | |
| 83735 | <1% | 368 | $563.87 | |
| 81001 | <1% | 726 | $563.48 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 56 | $507.41 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 28 | $498.60 |
| J3490 | Unclassified drugs | <1% | 463 | $433.55 |
| 94760 | <1% | 167 | $426.85 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 96 | $353.42 |
| 83605 | <1% | 164 | $352.76 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 36 | $332.73 |
| 81003 | <1% | 405 | $283.53 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 216 | $280.48 |
| 82962 | <1% | 361 | $279.93 | |
| 80061 | Lipid panel | <1% | 27 | $260.52 |
| 87040 | <1% | 45 | $246.86 | |
| 84145 | <1% | 61 | $244.31 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 595 | $236.15 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 52 | $234.56 |
| 84702 | <1% | 37 | $225.94 | |
| 87077 | <1% | 62 | $221.07 | |
| 86900 | <1% | 68 | $215.51 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 40 | $191.72 |
| 96376 | <1% | 76 | $188.94 | |
| 85379 | <1% | 70 | $180.20 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 505 | $138.95 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 89 | $133.10 |
| 86901 | <1% | 55 | $99.28 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 59 | $95.44 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 18 | $68.80 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 129 | $65.28 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 57 | $64.93 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 184 | $59.16 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 114 | $43.42 |
| J2704 | Injection, propofol, 10 mg | <1% | 43 | $36.64 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 74 | $34.10 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 91 | $29.52 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 81 | $25.83 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 12 | $15.84 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 69 | $15.40 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 31 | $3.66 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 16 | $3.14 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 63 | $2.56 |
| 00000 | 0% | 649 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCONNER, GARY (VP & CFO)
| Provider | Location | Paid |
|---|---|---|
| Chestnut Hill Hospital, LLC | Philadelphia, PA | $9.52M |
| Jennersville Hospital, LLC | West Grove, PA | $1.35M |
| West Grove Clinic Company LLC | West Grove, PA | $157K |
| Tower Health Medical Group | Wyomissing, PA | $98K |
| Tower Health Medical Group | Wyomissing, PA | $84K |
| STC Pediatrics LLC | Philadelphia, PA | $24K |
| Tower Drexel Academic Medical Group LLC | Philadelphia, PA | $18K |
| Tower Health Urgent Care, LLC | Kennett Square, PA | $9K |
| Tower Health Urgent Care, LLC | Philadelphia, PA | $8K |
| Tower Health Urgent Care, LLC | Philadelphia, PA | $4K |
| Tower Health Urgent Care, LLC | Doylestown, PA | $3K |
| Tower Health Medical Group | West Reading, PA | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.